TP53 and ovarian carcinoma: However, one study showed no significant association between TP53 mutation status and prognosis for patients who received platinum-based chemotherapy after analysing 45 FIGO stage IIC–III ovarian carcinomas (Smith-Sorensen et al, 1998).